Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.

Subjects

Subjects :

RNA metabolism
BREAST tumor risk factors
RISK assessment
DOCETAXEL
CISPLATIN
PATIENT safety
DRUG side effects
RESEARCH funding
BREAST tumors
STATISTICAL sampling
RANDOMIZED controlled trials
DESCRIPTIVE statistics
MESSENGER RNA
ADJUVANT chemotherapy
GENE expression profiling
RESEARCH
GEMCITABINE
PROGRESSION-free survival
CONFIDENCE intervals
EPIRUBICIN
CYCLOPHOSPHAMIDE
OVERALL survival
PROPORTIONAL hazards models

Details

Language :

English

ISSN :

17561833

Volume :

387

Issue :

8446

Database :

Complementary Index

Journal :

BMJ: British Medical Journal

Publication Type :

Academic Journal

Accession number :

180475411

Full Text :

https://doi.org/10.1136/bmj-2024-079603